These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12590733)

  • 1. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments.
    Gaubin M; Fanutti C; Mishal Z; Durrbach A; De Berardinis P; Sartorius R; Del Pozzo G; Guardiola J; Perham RN; Piatier-Tonneau D
    DNA Cell Biol; 2003 Jan; 22(1):11-8. PubMed ID: 12590733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses.
    De Berardinis P; Sartorius R; Fanutti C; Perham RN; Del Pozzo G; Guardiola J
    Nat Biotechnol; 2000 Aug; 18(8):873-6. PubMed ID: 10932158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides.
    Wang W; Man S; Gulden PH; Hunt DF; Engelhard VH
    J Immunol; 1998 Feb; 160(3):1091-7. PubMed ID: 9570521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase.
    van der Burg SH; Klein MR; van de Velde CJ; Kast WM; Miedema F; Melief CJ
    AIDS; 1995 Feb; 9(2):121-7. PubMed ID: 7536421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin.
    Zaghouani H; Kuzu Y; Kuzu H; Brumeanu TD; Swiggard WJ; Steinman RM; Bona CA
    Eur J Immunol; 1993 Nov; 23(11):2746-50. PubMed ID: 8223850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes.
    Buckner FS; Wipke BT; Van Voorhis WC
    Eur J Immunol; 1997 Oct; 27(10):2541-8. PubMed ID: 9368608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
    Hiltbold EM; Alter MD; Ciborowski P; Finn OJ
    Cell Immunol; 1999 Jun; 194(2):143-9. PubMed ID: 10383817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens.
    Cheng PC; Steele CR; Gu L; Song W; Pierce SK
    J Immunol; 1999 Jun; 162(12):7171-80. PubMed ID: 10358163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
    Svensson M; Pfeifer J; Stockinger B; Wick MJ
    Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules.
    Selby M; Erickson A; Dong C; Cooper S; Parham P; Houghton M; Walker CM
    J Immunol; 1999 Jan; 162(2):669-76. PubMed ID: 9916684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
    Ishioka GY; Fikes J; Hermanson G; Livingston B; Crimi C; Qin M; del Guercio MF; Oseroff C; Dahlberg C; Alexander J; Chesnut RW; Sette A
    J Immunol; 1999 Apr; 162(7):3915-25. PubMed ID: 10201910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.
    de Jong JM; Schuurhuis DH; Ioan-Facsinay A; Welling MM; Camps MG; van der Voort EI; Huizinga TW; Ossendorp F; Verbeek JS; Toes RE
    Immunology; 2006 Dec; 119(4):499-506. PubMed ID: 16995881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class II MHC molecules can use the endogenous pathway of antigen presentation.
    Nuchtern JG; Biddison WE; Klausner RD
    Nature; 1990 Jan; 343(6253):74-6. PubMed ID: 1967486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrocytes are potent stimulators of anti-virus cytotoxic T cells.
    Balmelli C; Ruggli N; McCullough K; Summerfield A
    J Leukoc Biol; 2005 Jun; 77(6):923-33. PubMed ID: 15767291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
    Rock KL; Clark K
    J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT; Umetsu DT; DeKruyff RH; Levy S
    J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells.
    West MA; Lucocq JM; Watts C
    Nature; 1994 May; 369(6476):147-51. PubMed ID: 8177319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.